Methods and compositions for treating viral infections
AssigneeDST Pharma, Inc.
InventorLu Wang
Life of this patent
Estimating the term…
Abstract
Nutraceutical compositions and methods of their use in treating Caliciviridae family viruses are provided. The viruses can be norovirus or sapovirus. An exemplary nutraceutical composition includes Fagopyrum dibotrys extract. Another nutraceutical composition for treating viral gastroenteritis includes 5, 7, 3′, 4′-tetrahydroxyflavan-3-ol C4-C8 dimers, quercetin, rutin, or a combination thereof. The nutraceutical compositions inhibit or reduce entry of Caliciviridae family viruses into intestinal epithelial cells of the subject.
Claims25
A method for inhibiting or reducing symptoms of viral gastroenteritis in a subject comprising:
- administering to the subject a composition comprising Fagopyrum diboyto extract and a pharmaceutically acceptable excipient in an amount effective to inhibit viral gastroenteritis in the subject.
A method for inhibiting or reducing symptoms of viral gastroenteritis in a subject comprising:
- administering to the subject a composition comprising 5, 7, 3′, 4′-tetrahydroxyflavan-3-ol C4-C8 dimers, quercetin, and a pharmaceutically acceptable excipient in an amount effective to inhibit viral gastroenteritis in the subject.
A method for prophylactically treating viral gastroenteritis in a subject at risk of viral infection comprising:
- administering to the subject an effective amount of a composition comprising 5, 7, 3′, 4′-tetrahydroxyflavan-3-ol C4-C8 dimers, quercetin, and a pharmaceutically acceptable excipient to inhibit or reduce entry of Caliciviridae family viruses into intestinal epithelial cells of the subject.
A compound according to Formula II
- wherein:
- rings A, B, C, and D are independently six-membered aryl or nitrogen-containing herteroaryl mono- or bicycylc ring systems containing zero or more nitrogen atoms such as phenyl, pryridine, pyrimidine, pyridazine, pyrazine, triazine, quinolone, quinazoline, isoquinoline, naphthalene, naphthyridine, indole, isoindole, cinnoline, phthalazine, quinoxaline, pteridine, purine, and benzimidazole.
- R1, R2, R3, R4, R5, R6, R7, R8, R9 and Rio are independently selected from —H, —F, —Cl, —Br, —CF3, —OH, —O—(C1-C12)-alkyl, —O—(C3-C12)-cyclocalkyl, —O—(C3-C12)-heterocycloalkyl, —NH3, —NH—(C1-C12)-alkyl, —NH—(C3-C12)-cyclocalkyl, —NH—(C3-C12)-heterocycloalkyl, —COOH, —CONH2, —CONH(C1-C12 alkyl), —CON(C1-C12 alkyl)2, —COO(C1-C12 alkyl), —CO(C1-C12 alkyl), —SH, —SO3H, or —CN.
- X and Y are independently selected from —O, —NH, —S, —N—(C1-C30)-alkyl, - or —(C1-C30)-alkyl,
- or a pharmaceutically relevant enantiomer, salt, or solvate thereof.
A compound according to Formula II
- wherein:
- R1, R2, R3, R4, R5, R6, R7, R8, R9 and Rio are independently selected from —H, —F, —Cl, —Br, —CF3, —OH, —O—(C1-C12)-alkyl, —O—(C3-C12)-cyclocalkyl, —O—(C3-C12)-heterocycloalkyl, —NH3, —NH—(C1-C12)-alkyl, —NH—(C3-C12)-cyclocalkyl, —NH—(C3-C12)-heterocycloalkyl, —COOH, —CONH2, —CONH(C1-C12 alkyl), —CON(C1-C12 alkyl)2, —COO(C1-C12 alkyl), —CO(C1-C12 alkyl), —SH, —SO3H, or —CN.
- X and Y are independently selected from —O, —NH, —S, —N—(C1-C30)-alkyl, - or —(C1-C30)-alkyl,
- or a pharmaceutically relevant enantiomer, salt, or solvate thereof.
A composition comprising:
- one or more of 5, 7, 3′, 4′-tetrahydroxyflavan-3-ol C4-C8 dimers according to Formula I, Formula II, or Formula III,
- quercetin,
- rutin,
- sapogenin,
- and optionally a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.